Lumibird (LBIRD) Q3 2024 TU earnings summary

Executive summary

• Q3 saw a growth upturn in the Medical Division (+8%) and stability in the Photonics Division (+0.2%).

• 9-month consolidated revenues reached €141.5m, up 2% year-over-year and stable on a like-for-like basis.

• Agreement signed to acquire the Continuum nanosecond laser product line from Amplitude Laser Group, enhancing the scientific market offering and North American presence.

Financial highlights

• Q3 revenue: €43.5m, up 4% year-over-year; 9-month revenue: €141.5m, up 2%.

• Photonics division 9-month revenue: €67.3m (+2%); Medical division: €74.2m (+2%).

• Medical laser treatment activity grew 6.5% to €58.5m, representing 79% of Medical sales.

Outlook and guidance

• Anticipates a very high level of activity in Q4.

• Confirms sales growth target of over 5% and EBITDA margin target above 16% of sales.